Diseases Studied

The Rare Diseases Clinical Research Network is an NIH-funded research network of 20 active consortia or research groups working to advance treatment for diseases that are rare. Use the search tools on this page to find the diseases we currently study. You can reach out to the indicated consortia or research groups for more information on those diseases and studies underway.

This network focuses on clinical research and does not generally support clinical care outside of research activities. To learn about other rare diseases, please visit the Genetic and Rare Diseases Information Center (GARD), which is an NIH program that helps the public find reliable information about rare and genetic diseases. Their staff are specialists. Contact them at 1-888-205-2311 or email GARDinfo@nih.gov.

All Diseases > Eosinophilic Gastrointestinal Disorders

Eosinophilic Gastrointestinal Disorders (EGID)

Disease Category: Eosinophilic Gastrointestinal Disorders

Eosinophilic gastrointestinal disorders are a group of chronic immune system disorders in which a type of white blood cell (eosinophils) build up in the gastrointestinal tract, causing inflammation or injury. These disorders include eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis.

Research groups studying this disease

Eosinophilic Gastrointestinal Disorders
CEGIR logo

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

View Disease Definition
CEGIR logo

Recruiting

CEGIR is conducting this study because they want to learn more about Eosinophilic Gastrointestinal Diseases (EGIDs). As part of that goal, one area of study will compare how well a patient feels – their symptoms – with what the tissue samples look like under a microscope. The study aims to answer a series of questions, including the following: - What if the tissue looks good, but you are still experiencing symptoms? - What if the symptoms have subsided, but the eosinophil counts haven’t changed?

This study is being conducted to determine the safety and effectiveness of a study drug called dupilumab in adolescents and adults with eosinophilic gastritis (EG) with or without esophageal and/or duodenal eosinophilia.

Supports people affected by eosinophilic gastrointestinal diseases and collaborates with global medical professionals and researchers.

Supports and enhances the lives of families living with eosinophilic disorders while educating those around us.

Improves the lives of patients and families affected by eosinophil-associated diseases through education, research, and advocacy.

Supports those suffering from eosinophilic gastrointestinal diseases (EGIDs) and raises substantial funding.